Author: Kumar, Surender; Tyagi, D K; Gupta, Arun
Date published: June 1, 2010
Journal code: JPTS
(ProQuest: ... denotes formula omitted.)
"Prodrugs Approach" is an integral part of drug development. This strategy increases the selectivity of drugs for intended target and there is a lower chance for attack on healthy cells which reduce side effects. Prodrug refers to a pharmacologically inactive compound that is converted to an active drug by a metabolic transformation1. The term "Prodrug" was first introduced by Albert's. This bioconversion or transformation may take place during and after absorption with in the body2-4. Now it is an established part of drug development10. It emphasizes on improving the desirable properties of drugs and decreasing the side effects9. Today many successful prodrugs have been developed with enhanced therapeutic efficiencies4-7 Prodrug approach is very effective and helpful in decreasing the problem related with solubility, absorption, distribution, site specificity, instability, toxicity, formulation and bioavailability problem3-7. Among various type of prodrugs, ester and amide prodrugs are most common type11. In body, these prodrugs break in to parent drug and coupled moiety. Stomach is mainly responsible for the breaking down the large molecules into smaller molecules which are easily absorbed by the small intestine. Prodrugs are frequently applied to mask polar and ionizable group of a drug molecule with the aim to improve membrane permeability and oral absorption20.
Diclofenac is one of the most important NSAID which effect on a variety of inflammatory mediators. It is an effective analgesic and anti-inflammatory agent with a good tolerability profile. But unfortunately like other NSAIDs it has some side effects like it affect GI system19, dyspepsia and low bioavailability22. The gastric side effects of Diclofenac is due to free carboxylic acid group. A possible way to solve this problem is to derivatize the free carboxylic functional group of Diclofenac to produce prodrug. Amide based Amidase sensitive prodrugs system has been used for Prodrugs of acids and amines8. Chlorzoxazone ester prodrugs of some acidic NSAIDs induced very little irritancy in the gastric mucosa21. Nebumetone is a prodrug, cause fewer GI ulcer than conventional NSAIDs25. Diethyl carbonate prodrug of Ibuprofen and naproxen undergo rapid transformation as compared to parent drugs24. Morpholino alkyl ester of naproxen was found more bioavailability and less irritating to gastric mucosa than parent drug26.
The result from the literature survey indicated that prodrugs have good chemical stability towards hydrolysis and more bioavailability.
Major side effect is that prostaglandin (which is necessary for mucosal defense) synthesis could be blocked by NSAIDs19. The result from the studies indicated that prodrugs had good chemical stability.
Keeping in view the wide ranging biological and pharmacological importance of prodrugs,
It was considered worth while to synthesize some new amide Prodrugs of diclofenac having biological and pharmacological interest. In the present research work, we synthesize some amide Prodrugs of Diclofenac by treating the parent drug with amino acid derivatives. Diclofenac was made to react with derivatives of amino acids, via, proline methyl ester, glutamic acid methyl ester, phenyl alanine methyl ester and sarcosine ethyl ester, in presence of Hydroxybenzotriazole (HOBT), 1-Ethyl- 3-(3-dimethylaminopropyl) carbodiimide- HCl (EDC- HCl) and N-methylmorpholine, in dichloromethane. Chemical structures of compounds were determined by ^sup 1^H NMR and FT-IR. NMR spectra were recorded and peaks were interpreted. In this study, the amino acid derivatives chooses to mask the free carboxylic acid group of diclofenac because it is condition for prodrug that the premoiety should be nontoxic and prodrugs formed could show varying degree of lipofilicity and less side effects. These amino acids are not harmful for living system.
1. Design, synthesize and characterization novel Prodrugs including Diclofenac and amino acid, which could improve the physiochemical and pharmacological properties of drug.
2. To increases the utility of Diclofenac by "Prodrugs Approach"
Material and Method:
Chemicals and Apparatus:
Chemicals obtained from S.D. fine and E Merck was of reagent grade used as such without further purification unless otherwise specified. Solvent used were double distilled on rota vapor. ^sup 1^H NMR spectra were recorded on a Brucker 400 MHz spectrometer in CDCl3 solution. IR were recorded with resolution 4.00 cm^sup -1^
Animals were housed in-group of 5 per cage under standard laboratory conditions, temperature and humidity. All experimental procedures were carried out under standard guidelines prescribed by Committee for the Purpose of Control and Supervision of Experiments on Animal and were approved by Institutional Animal Ethics Committee. 45 Albino mice (18-22 g) five in each group were used for analgesic activity while 45 Wistar rat (120- 170 g) five in each group were used for anti-inflammatory activity.
To a ice-water cooled solution of diclofenac (500 mg, 1.69 mmol) in dichloromethane (8.5 ml, 5.0 ml/mmol), Hydroxybenzotriazole (251 mg, 1.86 mmol) and 1-Ethyl-3-(3 dimethylaminopropyl) carbodiimide-HCl (EDC-HCl) (356.2 mg, 1.86 mmol) and N-methyl morpholine (341.4 mg, 3.38 mmol) was added and reaction mixture was stirred at 0°c for 5 minutes. A cooled solution of amino acid derivative (1.69 mmol) in dichloromethane (3 ml) was then added, and mixture was stirred at 0°c for additional 10 minutes. Removed the ice water bath and stirred the reaction mixture for 6-8 hrs. at room temperature.
Reaction completion was checked by TLC using Ethyl acetate-Hexane (1:1) as an eluting solvent. Reaction was quenched by addition of water (10 ml). The organic compound was extracted with ethyl acetate (3x20ml). Organic layer was washed with brine (3x20ml), dried over anhydrous Na^sub 2^SO^sub 4^ and concentrated in vacuum.
Purification was done by column chromatography using Silica (100-200) in ethyl acetate-Hexane.
Study Design for Pharmacological study (in vivo) of Synthesized Prodrugs:
Diclofenac as well as the Synthesized Prodrugs were evaluated for antiinflammatory and analgesic activity
Acetic acid - induced writhing
The animals were pre-treated with drug 45 minute before induction of writhing. The drug Diclofenac (100 mg/kg, i.p.) served as reference standard drug. Analgesic activity of synthesized derivatives of Diclofenac (100 mg/kg, i.p.) was accessed by counting the number of writhes induced by 0.6% acetic acid (10 ml/kg i.p.). The number of writhes per animal was counted for the next 10 minutes. Percentage protection against abdominal constriction was taken as an index of analgesia.
It was calculated as:
Carragennan Induced Paw edema
Experimental inflammation was induced according to the method described by Winter et al. (1962). Carrageenan (0.1 ml of 1%) was injected in to the right hind paw of each rat under the planter aponeurosis. The test groups of rats were treated with Derivatives of Diclofenac 100 mg/kg body weight, i.p. one hour before Carrageenan injection. At the same time the control group was administered the reference group was administered i.p. with an ethanolic solution of Diclofenac at a dose of 100mg/kg body weight. The displacement technique using the plethysmometer (IITC 520, USA) immediately and 1 and 2 h did the measurements of paw volume after the injection of Carrageenan. The inhibitory activity was calculated according to the formula
Percentage inhibition = (1- Vt/Vc) 100
Where Vt = Mean edema volume in the drug treated and
Vc = Mean edema volume in the drug control groups.
Results and Discussion:
Characterization of the Synthesized Prodrugs
Scheme-I: Preparation of methyl 1-(2-(2-(2, 6-dichlorophenylamino)phenyl)acetyl) pyrolidine-2-carboxylate
^sup 1^H NMR (400 MHz, CDCl3) δ 7.32 (dd, J=4.4, 8.1, 2H, Ar H), 7.18 (dd, J=1.4, 7.5, 1H, ArH), 7.11-7.06 (m, 1H, ArH), 6.95 (dt, J=2.3, 8.0, 1H, ArH), 6.90 (dt, J=1.2, 7.5, 1H, ArH), 6.51 (d, J=8.1, 1H, ArH), 4.55 (dd J=3.8, 8.4, 1H, NCH^sub 2^), 3.87 (s, 2H, CH^sub 2^-Ph), 3.80 (t, J=7.3, 2H, NCH^sub 2^), 3.70 (s, 3H, COOCH^sub 3^), 2.13-2.10 (m, 2H, ringCH^sub 2^), 2.05-2.02 (m, 2H, ringCH^sub 2^),
IR: 3340 cm^sup -1^ (NH), 1743 cm^sup -1^ (COOCH^sub 3^), 1668 cm^sup -1^ (amide)
Scheme-II: Preparation of 2-(2-(2,6- dichlorophenylamino)phenyl)-N-(2- ethoxyallyl)-N-methylacetamide
^sup 1^H NMR (400 MHz, CDCl^sub 3^) δ 7.32 (dd, J=3.8, 8.1, 2H, ArH), 7.18(dd, J=1.3, 7. 5, 1H, ArH), 7.11-7.08 (m, 1H, ArH), 6.96 (dt, J=4.8, 8.0, 1H, ArH), 6.92-6.89 (m, , 1H, ArH), 6.52 (d, J=7.9, 1H, ArH), 4.21 (q, 7.1, 2H, OCH^sub 2^), 4.20-4.15 (m, 2H, NCH^sub 2^), 3.91 (s, 2H, Ph-CH^sub 2^), 3.26 (s, 3H, NCH^sub 3^), 1.23 (t, J=7.2, 3H, CH^sub 3^)
IR: 3332 cm^sup -1^ (NH), 1738 cm^sup -1^ (COOCH^sub 3^), 1668 cm^sup -1^ (amide)
Scheme-III: Preparation of methyl 2(2-(2- (2,6- dichlorophenylamino)phenyl)acetamido) - 3-phenylpropanoate
^sup 1^H NMR (400 MHz, CDCl^sub 3^) δ 7.36 (d, J=1.6, 1H, ArH), 7.33 (s, 1H, ArH), 7.27 (d, J=1.5, 1H, ArH), 7.24 (dd, J=2.6, 6.0, 1H, ArH), 7.20 (dt, J=1.3, 4.7, 1H, ArH), 7.15 (dt, 1.6, 7.7, 1H, ArH), 7.05 (dd, J=1.4, 7.8, 1H, ArH), 7.00(d, J=8.0, 1H, ArH), 6.98- 6.96 (m, 2H, ArH), 6.66 (bs, 1H, HN-C=O), 6.56 (d, J=8.0, 1H, ArH), 6.41(d, J=7.8, 1H, ArH), 4.87 (dd, J=2.1, 5.9, 1H, CH*), 3.86 (s, 2H, CH^sub 2^-Ph), 3.72 (s, 3H, COOCH^sub 3^), 3.13-3.02 (m, 2H, CH^sub 2^-Ph),
IR: 3330 cm^sup -1^ (NH), 1734 cm^sup -1^ (COOCH^sub 3^), 1668 cm^sup -1^ (amide)
Scheme-IV: 4-(methoxycarbonyl)-2(2-(2- (2, 6-dichlorophenyl)amino)phenyl)amino) phenyl)acetamido)butanoate
^sup 1^H NMR (400 MHz, CDCl^sub 3^) δ 7.32 (dd, J=3.8, 8.1, 2H, ArH ), 7.18 (dd, J=1.3, 7.5, 1H, ArH ), 7.12 -7.08 (m, 1H, ArH ), 6.95 (dt, J=2.6, 8.0, 1H, ArH ), 6.92-6.88 ( m, 1H, ArH ), 6.51 (d, J=7.8, 1H, ArH), 4.58 (dt, J=5.2, 7.8, 1H, CH* ), 3.87 (s, 2H, CH^sub 2^- Ph ), 3.65 (s, 3H, OCH^sub 2^ ), 3.60 (s, 3H, OCH3 ), 2.33 ( t, J=7.6, 2H, CH2 ), 2.17 ( dt, J=7.5, 14.1, 1H, CH^sub 2^ ), 1.92 (dt, J=7.9, 14.2,1H, CH^sub 2^ )
IR: 3336 cm^sup -1^ (NH), 1735 cm^sup -1^ (COOCH^sub 3^) 1668 cm^sup -1^ (amide)
Physiochemical Properties of the Synthesized Prodrugs
Pharmacological study (in vivo) of Synthesized Prodrugs:
In the present study, amide Prodrugs of Diclofenac were successfully synthesized and the structures were confirmed by NMR and UR analysis. The free carboxylic group of Diclofenac was temporarily masked by amino acid derivatives to prevent the direct exposure of the mucous layer of the stomach to this free carboxylic acid group. Four amide Prodrugs of Diclofenac were synthesized by selecting corresponding amino acids viz. proline methyl ester, sarcosin ethyl ester, phenyl alanine methyl ester and glutamic acid methyl ester by direct coupling in the presence of NMM, HOBT and EDC-HCL. The selection of the amino acids was done in such a manner that the Prodrugs with varying degree of lipophilicity could be obtained. High solubility in various organic solvents was observed for the newly synthesized prodrugs indicating the lipophilic behavior. The physicochemical and solubility data are recorded in Table 1 and 2. All the Synthesized Prodrugs were found pharmacologically active as compared to control and were quantitatively less active than standard Diclofenac.
 Albert, A., Nature, 182:421, (1958)
 Ham, H., et al targeted Prodrug design to optimize Drug Discovery AAAPS Pharm Sci. 2000; 2 (1): article 6
 Dhaneshwar, S., Indian Journal of Pharmaceutical Science, 68(3), 286-294,(2006)
 Qizhenz, Y. et al Synthesis and evolution of carbamate produrgs of S Q109 Medicinal chemistry letters (2009)
 Mishra, S., Nucleic Acid Research Supplement, 277 (2002)
 Rao, H.S.P., Capping Drug: Development of Prodrug, (2003)
 Lenard. M. Nonstroidal Anti-inflammatory Drug and Phospholipids Prodrug, Gastroenterology. 990(1996)
 Prodrug of Amines, Molecules (2008), 13, 519- 547
 Bhosale. A. V., Agrawal, Indian Journal of Pharmaceutical Science, 68 (4), 425-431, (2006)
 Free encyclopedia.com
 Prodrug: Design and Clinical Application, Nature.com
 Encyclopedia of pharmaceutical technology
 Audra, L., Neltrexone Ester Prodrug Bioconversion in a human Epidermis Equivalent, (2006)
 Guangping, W., Journal of Medicinal Chemistry, 48(1), 256-261 (2005)
 Fang, J., Produrg Strategy for enhancing Drug Delivery via Skin, Current Drug discovery Technology, 3(3), 211-214, (2006)
 Huang, S., Bioorganic and Medicinal Chemistry Letters, 16, 3639-3641 (2006)
 Dhaneshwar, S., Bioorganic and Medicinal Chemistry Letters, 17(7), 1897-1902, (2007)
 Rahman, T., Indian Journal of Pharmaceutical Science, 36 (5), 332-333, (2004)
 John, L., Prostaglandin, NSAID,s and gastric mucosal protection, Physiological Review, 88: 1547-1565, 2008
 Prodrug Approach to Enhancinf the Oral Delivery of Poorly Permeable Drug by Valentino J.Stella
 Ahmad, Z., etal, Chloroxazone ester of some NSAI Carboxylic acids, Bioorganic and Medicinal Chemistry , 17, issue 10, 3665-3670, May (2009)
 Flower, Rod J. (2003), "The Development of Cox 2 Inhibitor." Nature Review Drug Discovery 2(3): 179-191
 Free encyclopedia.com
 Emil Samara et al. pharmacokinetics analysis of diethylcarbonate prodrugs of ibuprofen and naproxen Biopharm Drug Dispos. 1995 Apr; 16(3):201-10.
 Adis International Limited, Volume 7, Number 4, 2006, 262-266(5)
 Vijay K. Tammara et. al. Synthesis and Evaluation of Morpholinoalkyl Ester Prodrugs of Indomethacin and Naproxen pharmaceautical research 1993 1191-1199
Surender Kumar*1 , D.K.Tyagi1 and Arun gupta2
1Department of Chemistry DAV (P.G.) College, Dehradun-248001
2Department of Pharmaceutical Sciences, GJUS&T, Hisar- 125001